Soleno Therapeutics heads into its May 22 earnings release with a striking insider-selling cluster dominating the pre-print narrative.
The standout story is last Friday's executive selling. The CEO, Anish Bhatnagar, sold roughly $26 million worth of stock across multiple transactions — all at $53.00. The CFO, Jennifer Fulk, sold a further $3.6 million at the same price. A director and a senior vice president also sold on the same day, bringing the company's net insider value sold over 90 days to approximately $96 million. The activity is unusually concentrated and comes just days before the print.
The analyst community has already delivered its verdict, and it is largely cautious. Multiple firms — Wells Fargo, HC Wainwright, TD Cowen, Cantor Fitzgerald, and Wolfe Research — all downgraded the stock in early April, cutting targets from ranges of $85–$123 down to $53, exactly where the stock trades now. The consensus has since settled at hold across five analysts, with no current buys on the board. Cantor Fitzgerald suspended coverage entirely on May 19. The bull case centres on a pending acquisition at a 34% premium to current levels, fully funded with no financing contingencies, alongside VYKAT XR's FDA approval and projected peak sales of $2.3 billion. Bears point to European regulatory uncertainty for DCCR, safety questions around VYKAT XR tolerability, and the risk that the acquisition process hits delays.
Options positioning pulls in the other direction, however. The put/call ratio has dropped to 0.78 — nearly 2.6 standard deviations below its 20-day average of 0.97 — the most call-heavy reading in recent months. That points to unusual demand for upside exposure, even as insiders and analysts lean cautious. Short interest at 11.2% of the free float rose 20% over the past week, yet the borrow market remains relaxed: availability is around 464%, well above the 52-week low of 313%, and the cost to borrow at 1.3% has climbed sharply from under 0.5% but stays far below any squeeze territory.
The May 22 print will test whether the pending acquisition narrative holds, or whether the concentrated insider selling two trading days before earnings signals something the options market has not yet priced.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
